Patent Issued for Mitapivat therapy and modulators of cytochrome P450 (USPTO 11878049).

A patent has been issued to Agios Pharmaceuticals Inc. for their therapy using mitapivat and modulators of cytochrome P450. Mitapivat is an allosteric activator of pyruvate kinase R (PKR) and is currently being studied in clinical trials for the treatment of pyruvate kinase deficiency (PKD), hemolytic anemia, and thalassemia. The patent describes methods of treating these conditions by administering mitapivat along with inhibitors or inducers of cytochrome P450 3A4/5 (CYP3A4/5) or p-glycoprotein. This research provides potential treatment options for individuals with these hematologic diseases. [Extracted from the article]